Literature DB >> 30145829

Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.

Violetta Rozani1, Tanya Gurevich2,3, Nir Giladi2,3, Baruch El-Ad4, Judith Tsamir4, Beatriz Hemo4, Chava Peretz1.   

Abstract

BACKGROUND: Higher levels of serum cholesterol are well-established risk factors for coronary artery disease and stroke. The role of serum cholesterol in neurodegeneration is not clear.
OBJECTIVE: We evaluated the association between serum cholesterol levels over time and the risk of Parkinson's disease (PD) among statin-free individuals.
METHODS: A population-based cohort study of 261,638 statin-free individuals (aged 40-79 years at their first serum cholesterol test, 42.7% men), with repeated measures of total, low, and high-density lipoprotein cholesterol was performed from 1999 to 2012. Individuals were followed from their first cholesterol test until PD incidence, death, or end of study. The PD incidence was assessed using a validated antiparkinsonian-drug tracing approach. Cox models stratified by sex and age with time-dependent cholesterol variables were applied to estimate PD hazard ratios.
RESULTS: A total of 764 (3.3% patients aged 65 + years) incident PD cases were detected during a mean follow-up of 7.9 (±3.6) years. Among men, the middle and upper tertiles of total and low-density lipoprotein cholesterol compared to the lowest were significantly associated with a lower PD risk. Age-pooled hazard ratios (95% confidence interval) for middle and upper tertiles were 0.82 (0.66-1.01) and 0.71 (0.55-0.93), respectively, for total cholesterol, and 0.80 (0.65-0.98) and 0.72 (0.54-0.95) respectively, for low-density lipoprotein cholesterol. Among women, the association between total and low-density lipoprotein cholesterol levels with PD risk was not significant. Null results were found for both sexes for high-density lipoprotein cholesterol.
CONCLUSIONS: Higher levels of total and low-density lipoprotein cholesterol among men over time indicated a decreased PD risk. The potential role of cholesterol in disease protection warrants further investigation.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; cholesterol levels over time; statin-free cohort study

Mesh:

Substances:

Year:  2018        PMID: 30145829     DOI: 10.1002/mds.27413

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  21 in total

1.  Subjects at risk of Parkinson's disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study.

Authors:  Makoto Hattori; Takashi Tsuboi; Katsunori Yokoi; Yasuhiro Tanaka; Maki Sato; Keisuke Suzuki; Yutaka Arahata; Akihiro Hori; Motoshi Kawashima; Akihiro Hirakawa; Yukihiko Washimi; Hirohisa Watanabe; Masahisa Katsuno
Journal:  J Neurol       Date:  2020-02-07       Impact factor: 4.849

Review 2.  Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.

Authors:  Alexey M Petrov; Irina A Pikuleva
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 3.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

Review 4.  The Role of Lipids in Parkinson's Disease.

Authors:  Helena Xicoy; Bé Wieringa; Gerard J M Martens
Journal:  Cells       Date:  2019-01-07       Impact factor: 6.600

Review 5.  Parkinson's Disease in Women and Men: What's the Difference?

Authors:  Silvia Cerri; Liudmila Mus; Fabio Blandini
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

Review 6.  Cholesterol Metabolism in the Brain and Its Association with Parkinson's Disease.

Authors:  Uram Jin; Soo Jin Park; Sang Myun Park
Journal:  Exp Neurobiol       Date:  2019-10-31       Impact factor: 3.261

7.  Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease.

Authors:  Katsunori Yokoi; Makoto Hattori; Yuki Satake; Yasuhiro Tanaka; Maki Sato; Atsushi Hashizume; Akihiro Hori; Motoshi Kawashima; Akihiro Hirakawa; Hirohisa Watanabe; Masahisa Katsuno
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

8.  Serum lipid profile among sporadic and familial forms of Parkinson's disease.

Authors:  Daniel Macías-García; María Teresa Periñán; Laura Muñoz-Delgado; María Valle Jimenez-Jaraba; Miguel Ángel Labrador-Espinosa; Silvia Jesús; Dolores Buiza-Rueda; Carlota Méndez-Del Barrio; Astrid Adarmes-Gómez; Pilar Gómez-Garre; Pablo Mir
Journal:  NPJ Parkinsons Dis       Date:  2021-07-16

9.  Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.

Authors:  Avner Thaler; Shani Shenhar-Tsarfaty; Yanay Shaked; Tanya Gurevich; Nurit Omer; Anat Bar-Shira; Mali Gana-Weisz; Orly Goldstein; Meir Kestenbaum; Jesse M Cedarbaum; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

10.  Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson's Disease Severity.

Authors:  Wanlin Yang; Zihan Chang; Rongfang Que; Guomei Weng; Bin Deng; Ting Wang; Zifeng Huang; Fen Xie; Xiaobo Wei; Qin Yang; Mengyan Li; Kefu Ma; Fengli Zhou; Beisha Tang; Vincent C T Mok; Shuzhen Zhu; Qing Wang
Journal:  Front Aging Neurosci       Date:  2020-03-06       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.